At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALT Altimmune, Inc.
Trading 04-02 11:09:55 EDT
4.85
+0.11
+2.21%
| High4.85 | Low4.65 | Vol717.77K |
| Open4.67 | D1 Closing4.75 | Amplitude4.22% |
| Mkt Cap373.52M | Tradable Cap341.72M | Total Shares77.01M |
| T/O3.43M | T/O Rate1.02% | Tradable Shares70.46M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Altcoin Listings Spark Buzz in Crypto World
CoinMarketCap · 03-26
Coinbase to List ALT, PENDLE, and L3
Blockbeats · 03-26
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
Business Wire · 03-24
ALT Soars Over 18% Briefly Before Falling Back, Currently Trading at $0.038
Blockbeats · 03-20
Coinbase Adds ALT, PENDLE, and L3 to Asset Listing Roadmap
Blockbeats · 03-20
Press Release: MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update
Dow Jones · 03-20
Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones · 03-18
Altimmune call volume above normal and directionally bullish
TIPRANKS · 03-14
Altimmune Price Target Maintained With a $25.00/Share by Citizens Capital Markets
Dow Jones · 03-14
Altimmune Shares up 4.5% on Plans to Test Obesity Drug for Alcohol Use Disorder, Other Conditions
THOMSON REUTERS · 03-14
BRIEF-Altimmune Inc Phase 2 AUD Trial For Pemvidutide Expected In Q2 2025
Reuters · 03-13
BUZZ-Altimmune gains on plans to test weight-loss drug for alcohol use disorder, other conditions
Reuters · 03-13
Altimmune Inc - Phase 2 AUD Trial for Pemvidutide Expected in Q2 2025
THOMSON REUTERS · 03-13
ALT Resources PLC Publishes Annual Report for 2024
TIPRANKS · 03-11
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
PR Newswire · 03-08
Altimmune (ALT) Initiated with a Hold at William Blair
TIPRANKS · 03-05
Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones · 03-03
William Blair Initiates Altimmune at Market Perform
MT Newswires Live · 02-28
Altimmune Initiated at Market Perform by William Blair
Dow Jones · 02-28
Altimmune Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line
Simply Wall St. · 02-28
Introduction
Company Name.
Altimmune, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App